Annexin A5 Inhibits Endothelial Inflammation Induced by Lipopolysaccharide-Activated Platelets and Microvesicles via Phosphatidylserine Binding
Sepsis is caused by a dysregulated immune response to infection and is a leading cause of mortality globally. To date, no specific therapeutics are available to treat the underlying septic response. We and others have shown that recombinant human annexin A5 (Anx5) treatment inhibits pro-inflammatory...
Saved in:
Main Authors: | Brent J. Tschirhart (Author), Xiangru Lu (Author), Janice Gomes (Author), Arundhasa Chandrabalan (Author), Gillian Bell (Author), David A. Hess (Author), Guangxin Xing (Author), Hong Ling (Author), Dylan Burger (Author), Qingping Feng (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2023-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Therapeutic Potential of Annexins in Sepsis and COVID-19
by: Louise Mui, et al.
Published: (2021) -
Pharmacokinetics of recombinant human annexin A5 (SY-005) in patients with severe COVID-19
by: Brent J. Tschirhart, et al.
Published: (2024) -
Endothelial Microvesicles and Soluble Markers of Endothelial Injury in Critically Ill Newborns
by: Veronika Vítková, et al.
Published: (2018) -
New Therapeutic Strategies in Retinal Vascular Diseases: A Lipid Target, Phosphatidylserine, and Annexin A5-A Future Theranostic Pairing in Ophthalmology
by: Anna Frostegård, et al.
Published: (2024) -
Differential Modulation of Annexin I Binding Sites on Monocytes and Neutrophils
by: H. S. Euzger, et al.
Published: (1999)